<DOC>
	<DOC>NCT01301456</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.</brief_summary>
	<brief_title>Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<criteria>History of Type 2 diabetes and currently being treated with high dose metformin BMI between 22.0 and 40.0 kg/m2 HbA1c between 7.010.0% Fasting Cpeptide &gt;1.21 ng/mL History of clinically significant chronic conditions other than Type 2 diabetes not well controlled by either diet or medications Treatment with antidiabetic therapies other than metformin History of allergic or anaphylactic reaction to any therapeutic or diagnostic monoclonal antibody Males or women of childbearing potential</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>CVX-096</keyword>
</DOC>